MaxCyte Inc (LON: MXCT) said it was making “significant progress” with an early-stage cancer drug developed using its CARMA technology.
MCY-M11 is currently in phase I clinical trials in people with difficult-to-treat ovarian cancer and peritoneal mesothelioma, which affects the abdomen lining.
WATCH: MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials
The objective of a study of this kind is to assess whether the drug is safe and well-tolerated.
Having treated a second group, called a cohort, there have been no “dose-limiting toxicities, infusion-related adverse events, on-target or off-target toxicities, or other unwanted events”.
The third group of patients will receive a higher dose of MCY-M11 than those people who were given it earlier in the trial.
"We are making significant progress with our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform. Furthermore, the on-going trial continues to demonstrate the feasibility of our one-day cell therapy manufacturing process," said MaxCyte’s chief medical officer, Claudio Dansky Ullmann.
"We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options."
The drug is what’s called a chimeric antigen receptor therapy, which gives T-cells the ability to target a specific protein. T-cells are part of the immune system and circulate scanning for cellular abnormalities and infections.